Miniature subcutaneous slow-release osmotic pump

Abstract

The utility model relates to the technical field of drug delivery pumps, in particular to a miniature subcutaneous sustained-release osmotic pump which comprises a degradable soft silicon capsule bag, a plurality of drug delivery pipes, a plurality of drug delivery pipes, a plurality of drug delivery pipes, a plurality of drug delivery pipes and a plurality of drug delivery pipes. The degradable soft silicon capsule bag is of a flexible cavity structure and is internally provided with a plurality of degradable independent capsule bags. And the medicine flow channel is communicated with each degradable independent capsule bag, and the medicine flow channel is provided with a total medicine inlet which extends towards the outer part of the degradable soft silicon capsule bag. The degradable soft silica gel capsule bag is in a square bag shape and is made of soft degradable soft silica gel materials, so that the degradable soft silica gel capsule bag can be well attached to subcutaneous gaps, remarkable protrusion of a traditional cylindrical pump is avoided, and the problem that mice bite with one another is effectively solved.

Description

Technical Field

[0001] The utility model relates to the technical field of drug delivery pumps, in particular to a micro subcutaneous sustained-release osmotic pump. Background Art

[0002] In life science research, it is often necessary to apply drug-induced disease models or drug-treated disease models. Traditional drug administration methods include oral administration and long-term multiple injections, which often have the disadvantages of large fluctuations in blood drug levels and related toxicity caused by drug instability. Compared with traditional oral, intraperitoneal or intravenous administration routes, subcutaneous osmotic administration has the advantages of small drug dose loss and small drug concentration fluctuations, which can effectively avoid the defects of traditional drug administration methods. Compared with traditional drug administration methods, it can be implanted subcutaneously or intraperitoneally in experimental animals or targeted at specific parts to continuously administer drugs at a precisely controllable rate. Continuous administration through osmotic sustained-release pumps can establish a variety of animal disease models, as well as research in many fields such as drug and molecular screening, pharmacology, pharmacokinetics and efficacy. Therefore, implantable sustained-release pumps have become an important way to deliver drugs in life science experimental research.

[0003] The shell of the mainstream osmotic pump currently used in life science research is a rigid semipermeable membrane material, such as Figure 1 As shown in the figure, in long-term practice, we found that rigid shells are prone to animal skin abrasion, drug pump dislocation, mutual biting between animals in the same cage, secondary skin infection and other problems. These adverse events harm experimental animals and affect the observation of scientific research results. Secondly, because the drug release port of this type of osmotic pump is small, the local skin continuously absorbs the drug under high pressure, which is prone to drug-related adverse reactions such as necrosis and drug leakage. Utility Model Content

[0004] The utility model provides a micro subcutaneous sustained-release osmotic pump, whose degradable soft silicone capsule bag has a square bag shape and is made of soft degradable soft silicone material, so that the degradable soft silicone capsule bag can have a good fit with the subcutaneous gap, avoiding the significant protrusion of a traditional cylindrical pump, thereby effectively preventing the problem of biting between mice.

[0005] In order to achieve the above-mentioned purpose, the utility model provides the following technical solutions: a micro subcutaneous sustained-release osmotic pump, comprising: a degradable soft silicone capsule bag, the degradable soft silicone capsule bag is a flexible cavity structure, and a plurality of degradable independent capsule bags are arranged inside; a drug flow channel, the drug flow channel is connected with each of the degradable independent capsule bags, and the drug flow channel is provided with a total drug inlet extending to the outside of the degradable soft silicone capsule bag; the degradable soft silicone capsule bag and each of the degradable independent capsule bags (2) are respectively set to different degradation rates.

[0006] Preferably, each of the degradable independent capsules is fixedly distributed in the degradable soft silicone capsule bag in a two-dimensional matrix shape, and each of the degradable soft silicone capsule bags is set with a different outer wall thickness to achieve a different degradation rate.

[0007] Preferably, a one-way valve flap is provided at one end of the drug flow channel corresponding to each of the degradable independent pouches.

[0008] Preferably, each of the degradable independent capsules is filled with an equal amount of the pharmaceutical agent.

[0009] Preferably, the degradable soft silicon capsule bag and the drug flow channel are both made of PLGA material.

[0010] The utility model has the beneficial effects that the degradable soft silicone capsule bag is a square bag-shaped shape, and its material is a soft degradable soft silicone material, so that the degradable soft silicone capsule bag can have a good fit with the subcutaneous gap, avoiding the significant protrusion of the traditional cylindrical pump, thereby effectively preventing the problem of biting between mice. At the same time, the design of the degradable soft silicone capsule bag significantly reduces the skin tension and significantly reduces the probability of skin damage, necrosis and infection. The degradable soft silicone capsule bag and the degradable independent capsule bag show the characteristics of gradient degradation at intervals of 24 hours by adjusting the component ratio of PLGA, so that the degradable soft silicone capsule bag and the degradable independent capsule bag are gradually degraded, thereby achieving the effect of stable drug release and ensuring that the daily drug dose absorbed by mice through the subcutaneous is constant. At the same time, because the drug release contact area is significantly wider than the traditional design, the subcutaneous absorption pressure is small, which effectively avoids the local skin necrosis, perforation and secondary drug leakage and loss caused by drug irritation and vasoconstriction drugs in the traditional micro pump, and reduces the risk of experimental failure. The one-way valve disc locks the medicine in each filled independent biodegradable bag, thereby preventing the problem of uneven medicine caused by operating force during the hot melt sealing process. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] In order to more clearly illustrate the embodiments of the utility model or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0012] Figure 1 This is a cross-sectional view of the mainstream osmotic pump structure;

[0013] Figure 2 It is a schematic diagram of the internal structure of the utility model.

[0014] In the figure: 1. Degradable soft silicone capsule bag; 2. Degradable independent capsule bag; 3. Drug flow channel; 4. Main drug inlet; 6. One-way valve disc. DETAILED DESCRIPTION

[0015] The following will be combined with the drawings of the utility model to clearly and completely describe the technical solution of the utility model. Obviously, the described embodiments are only part of the embodiments of the utility model, not all of the embodiments. Based on the embodiments of the utility model, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the utility model.

[0016] according to Figure 2 As shown, a micro subcutaneous sustained-release osmotic pump comprises: a degradable soft silicone capsule bag 1, which is a flexible cavity structure and has a plurality of degradable independent capsule bags 2 inside; a drug flow channel 3, which is connected to each of the degradable independent capsule bags 2, and the drug flow channel 3 is provided with a total drug inlet 4 extending to the outside of the degradable soft silicone capsule bag 1.

[0017] In this configuration, the degradable soft silicone capsule bag 1 is in a square bag shape, and is made of soft degradable soft silicone material, so that the degradable soft silicone capsule bag 1 can have a good fit with the subcutaneous gap, avoiding the significant protrusion of the traditional cylindrical pump, thereby effectively preventing the problem of biting between mice. At the same time, the design of the degradable soft silicone capsule bag 1 significantly reduces skin tension and significantly reduces the probability of skin damage, necrosis and infection.

[0018] Among them, each of the degradable independent capsules 2 is fixedly distributed in the degradable soft silicone capsule bag 1 in a two-dimensional matrix; the degradable soft silicone capsule bag 1 and each of the degradable independent capsules 2 are set to have different degradation rates. That is, the degradable soft silicone capsule bag 1 and the drug flow channel 3 are both made of PLGA. And each of the degradable independent capsules 2 is filled with an equal amount of medicine.

[0019] As a preferred embodiment, the degradable independent pouches are fixedly arranged in a 3*3 arrangement in the degradable soft silicone capsule bag, and the drug filling amount of each degradable independent pouch is 20u l, so that the total drug filling amount of the degradable soft silicone capsule bag is 180u l. At the same time, through the gradient design of the thickness of each degradable independent pouch, the degradable independent pouch with the thinnest outer wall is degraded first, thereby achieving early drug release, and the last one is degraded the latest. The gradient pouch thickness ensures the requirement of gradual release, thereby avoiding excessive drug concentration and causing permeability damage.

[0020] In this setting, the degradable soft silicone capsule bag 1 and the degradable independent capsule bag 2 show the characteristics of gradient degradation at intervals of 24 hours by adjusting the composition ratio of PLGA, so that the degradable soft silicone capsule bag 1 and the degradable independent capsule bag 2 are gradually degraded, thereby achieving the effect of stable drug release and ensuring that the daily drug dose absorbed subcutaneously by mice is constant. At the same time, because the drug release contact area is significantly wider than the traditional design and the subcutaneous absorption pressure is small, the local skin necrosis and perforation secondary to drug leakage and loss caused by drug irritation and vasoconstriction drugs in traditional micropumps are effectively avoided, reducing the risk of experimental failure.

[0021] The drug flow channel 3 is provided with a one-way valve flap 6 at one end corresponding to each of the degradable independent pouches 2. In this arrangement, when the medicine is injected into the main drug inlet 4 through a syringe, the one-way valve flap 6 locks the medicine in each filled degradable independent pouch 2, ensuring that the medicine will not leak out of the degradable independent pouch after filling, and is only released through the degradation of the degradable independent pouch, ensuring that the medicine released from each degradable independent pouch is constant.

[0022] The above is only a specific implementation of the utility model, but the protection scope of the utility model is not limited thereto. Any technician familiar with the technical field can easily think of changes or substitutions within the technical scope disclosed by the utility model, which should be included in the protection scope of the utility model. Therefore, the protection scope of the utility model should be based on the protection scope of the claims.

Claims

1. A micro subcutaneous sustained-release osmotic pump, characterized in that ,include: A degradable soft silicon capsule bag (1), wherein the degradable soft silicon capsule bag (1) is a flexible cavity structure and is provided with a plurality of degradable independent capsule bags (2) inside; A drug flow channel (3), the drug flow channel (3) being connected to each of the degradable independent capsule bags (2), and the drug flow channel (3) being provided with a total drug inlet (4) extending to the outside of the degradable soft silicon capsule bag (1); The degradable soft silicon capsule bag (1) and each of the degradable independent capsule bags (2) are respectively set to have different degradation rates.

2. The micro subcutaneous sustained-release osmotic pump according to claim 1, characterized in that: The individual degradable independent capsules (2) are fixedly distributed in the degradable soft silicone capsule bag (1) in a two-dimensional matrix, and each of the degradable soft silicone capsule bags (1) is set with a different outer wall thickness to achieve a different degradation rate.

3. The micro subcutaneous sustained-release osmotic pump according to claim 1, characterized in that: The drug flow channel (3) is provided with a one-way valve flap (6) at one end corresponding to each of the degradable independent pouches (2).

4. The micro subcutaneous sustained-release osmotic pump according to claim 1, characterized in that: Each of the degradable independent capsules (2) is filled with an equal amount of medicine.

5. The micro subcutaneous sustained-release osmotic pump according to claim 1, characterized in that: The degradable soft silicon capsule bag (1) and the drug flow channel (3) are both made of PLGA material.

Images